Cancer Stories
Search by cancer type, stage, biomarker or treatment to find people who've been exactly where you are.
Discuss
PatientSavvy: Join us
A 70-year-old woman with colorectal adenocarcinoma entered the TAPUR study after her cancer had progressed on oxaliplatin and capecitabine chemotherapy. Genomic testing identified a CD74-NRG1 fusion, and no KRAS alteration was detected.
She started afatinib in March 2021 as a biomarker-directed treatment. Unlike some of the other NRG1-fusion cancers in the same study, her disease did not respond. Clinical progression was documented after 8 weeks, although imaging measurements showed only a small change in target-lesion size. She remained on study treatment for a longer period before stopping.
She died in November 2021. Her experience illustrates that the same rare biomarker does not guarantee the same treatment response across different patients or tumor types.
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer